1. Home
  2. AKTX vs POCI Comparison

AKTX vs POCI Comparison

Compare AKTX & POCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • POCI
  • Stock Information
  • Founded
  • AKTX N/A
  • POCI 1982
  • Country
  • AKTX United States
  • POCI United States
  • Employees
  • AKTX N/A
  • POCI N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • POCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • AKTX Health Care
  • POCI Health Care
  • Exchange
  • AKTX Nasdaq
  • POCI Nasdaq
  • Market Cap
  • AKTX 25.1M
  • POCI 32.9M
  • IPO Year
  • AKTX N/A
  • POCI N/A
  • Fundamental
  • Price
  • AKTX $0.82
  • POCI $4.19
  • Analyst Decision
  • AKTX Strong Buy
  • POCI
  • Analyst Count
  • AKTX 2
  • POCI 0
  • Target Price
  • AKTX $3.30
  • POCI N/A
  • AVG Volume (30 Days)
  • AKTX 138.6K
  • POCI 13.9K
  • Earning Date
  • AKTX 11-14-2025
  • POCI 09-29-2025
  • Dividend Yield
  • AKTX N/A
  • POCI N/A
  • EPS Growth
  • AKTX N/A
  • POCI N/A
  • EPS
  • AKTX N/A
  • POCI N/A
  • Revenue
  • AKTX N/A
  • POCI $19,091,269.00
  • Revenue This Year
  • AKTX N/A
  • POCI N/A
  • Revenue Next Year
  • AKTX N/A
  • POCI N/A
  • P/E Ratio
  • AKTX N/A
  • POCI N/A
  • Revenue Growth
  • AKTX N/A
  • POCI N/A
  • 52 Week Low
  • AKTX $0.57
  • POCI $3.77
  • 52 Week High
  • AKTX $2.91
  • POCI $5.48
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 49.55
  • POCI 41.99
  • Support Level
  • AKTX $0.70
  • POCI $4.05
  • Resistance Level
  • AKTX $0.83
  • POCI $4.30
  • Average True Range (ATR)
  • AKTX 0.06
  • POCI 0.10
  • MACD
  • AKTX 0.00
  • POCI 0.01
  • Stochastic Oscillator
  • AKTX 85.71
  • POCI 55.96

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About POCI Precision Optics Corporation Inc.

Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.

Share on Social Networks: